Comparative Pharmacology
Head-to-head clinical analysis: AVMAPKI FAKZYNJA CO PACK COPACKAGED versus TIVICAY PD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVMAPKI FAKZYNJA CO PACK COPACKAGED versus TIVICAY PD.
AVMAPKI FAKZYNJA CO-PACK (COPACKAGED) vs TIVICAY PD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AVMAPKI FAKZYNJA is a co-packaged regimen containing a selective inhibitor of mutated KRAS G12C (avmapki) and an inhibitor of the SH2 domain-containing phosphatase 2 (SHP2) (fakzynja). The combination blocks MAPK signaling by inhibiting both KRAS G12C and SHP2, which is required for RAS-mediated signaling.
Tivicay PD (dolutegravir) is an HIV-1 integrase strand transfer inhibitor (INSTI) that inhibits the catalytic activity of HIV-1 integrase, preventing the integration of viral DNA into host chromosomal DNA, which is essential for viral replication.
Not applicable: AVMAPKI FAKZYNJA is a non-standard placeholder name. No established dosing.
50 mg orally once daily, with or without food.
None Documented
None Documented
Avmapi terminal half-life 12-15 hours; fakzynja 8-10 hours. Co-packaged: combined effective half-life 11-13 hours; dosing interval adjusted to 12 hours.
Terminal elimination half-life is approximately 12-15 hours in adults, supporting once-daily dosing.
Renal excretion of avmapi is 30% unchanged; fakzynja is 70% metabolized hepatically with 60% renal excretion of metabolites and 30% biliary/fecal. Co-packaged: combined renal clearance accounts for 45% total dose, biliary/fecal 35%, and metabolism 20%.
Primarily metabolized by UGT1A1 with minor CYP3A4; 53% of dose recovered in feces (30% as unchanged drug) and 31% in urine (18% as unchanged drug).
Category C
Category C
Antiretroviral
Antiretroviral, integrase inhibitor